Leap Therapeutics Headquarters

Looking for information about Leap Therapeutics Headquarters? The links below have collected all the necessary data.

Leap Therapeutics

https://www.leaptx.com/

Leap Therapeutics is developing novel cancer drugs. Our monoclonal antibodies are designed to target key cellular pathways that enable cancer to grow and proliferate, known as cancer cell signaling, and pathways that help the body’s immune system to identify and treat cancer. Therapies targeting cancer cell signaling and T cells offer new ...

Leap Therapeutics - Overview, News & Competitors ...

https://www.zoominfo.com/c/Leap-Therapeutics-Inc/373356016

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a human... Read More. Headquarters: 47 Thorndike St, Ste B1-1, Cambridge, Massachusetts, 02142, United States.Employees: 23

Leap Therapeutics - Crunchbase Company Profile & Funding

https://www.crunchbase.com/organization/leap-therapeutics

[email protected]

About Leap Therapeutics

https://www.leaptx.com/about/

Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01. 2020. Leap Therapeutics Announces Orphan Drug Designation of DKN-01 for the Treatment of Gastric/Gastroesophageal Junction Cancer and Closes $45 million Public Offering of Common Stock.

Leap Therapeutics LinkedIn

https://www.linkedin.com/company/leap-therapeutics

Leap Therapeutics 1,116 followers on LinkedIn. Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of ...

Leap Therapeutics Company Profile: Stock Performance ...

https://pitchbook.com/profiles/company/152468-47

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1.

Management Page Leap Therapeutics

https://www.leaptx.com/management-page

Doug Onsi has served as Leap’s Chief Financial Officer, Treasurer and Secretary since 2011 and became the President & CEO in April of 2020. He has been at HealthCare Ventures since 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc. which was sold to Roche Holdings, Inc.

Investors Leap Therapeutics, Inc.

https://investors.leaptx.com/

Jul 07, 2021 · Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation. Jul 26, 2021. Leap Therapeutics to Present at the ESMO 2021 Virtual Congress. Jul 07, 2021. Leap Therapeutics to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference. View All.

Leap Therapeutics Stock Forecast, Price & News (NASDAQ:LPTX)

https://www.marketbeat.com/stocks/NASDAQ/LPTX/

Aug 10, 2021 · Where are Leap Therapeutics' headquarters? Leap Therapeutics is headquartered at 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. How can I contact Leap Therapeutics? Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141.3.5/5

Leap Therapeutics and Macrocure Announce Definitive Merger ...

https://www.prnewswire.com/news-releases/leap-therapeutics-and-macrocure-announce-definitive-merger-agreement-591595721.html

Aug 29, 2016 · Leap Therapeutics is an immuno-oncology company with two clinical stage programs. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1 ...

Have you found Leap Therapeutics Headquarters information?